Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a buy rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, September 14th. Gabelli began coverage on Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a buy rating and a $25.00 price target on the stock. Piper Jaffray Cos. restated a buy rating and issued a $27.00 price target (up from $26.00) on shares of Collegium Pharmaceutical in a research note on Thursday, June 23rd. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, July 26th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 16.39 on Thursday. The firm has a 50 day moving average price of $11.02 and a 200-day moving average price of $14.37. Collegium Pharmaceutical has a 52 week low of $8.24 and a 52 week high of $30.58. The firm’s market capitalization is $385.62 million.
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. Equities research analysts predict that Collegium Pharmaceutical will post ($3.86) EPS for the current fiscal year.
In other news, Director John A. Fallon bought 2,375 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were bought at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the transaction, the director now owns 2,375 shares in the company, valued at $25,151.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 37.93% of the company’s stock.
A number of hedge funds have recently bought and sold shares of COLL. Nationwide Fund Advisors increased its stake in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,665 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in Collegium Pharmaceutical during the second quarter worth approximately $122,000. Royal Bank of Canada increased its stake in Collegium Pharmaceutical by 794.0% in the first quarter. Royal Bank of Canada now owns 11,300 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 10,036 shares during the last quarter. Rhumbline Advisers purchased a new stake in Collegium Pharmaceutical during the second quarter worth approximately $143,000. Finally, A.R.T. Advisors LLC purchased a new stake in Collegium Pharmaceutical during the second quarter worth approximately $148,000. Institutional investors own 62.13% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.